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A needle biopsy of a mass in the right breast of a 36-year-old woman revealed invasive 
ductal carcinoma (IDC), and approximately 20% of cancer cells showed unequivocal 
membranous staining with the HercepTestTM. After systemic therapy with trastuzumab 
and paclitaxel followed by FEC (fluorouracil + epirubicin + cyclophosphamide), a right 
mastectomy was performed. By histological and immunohistochemical examinations, 
the resected tumor consisted mainly of E-cadherin-negative invasive lobular carcinoma 
(ILC), and the rest was ERBB2-positive IDC; thus, the diagnosis was mixed ductal and 
lobular carcinoma. Multiplex ligation-dependent probe amplification and fluorescence 
in situ hybridization (FISH) analyses revealed that ILC and IDC shared high-level 
amplification of CCND1 in homogeneously staining regions (HSR) and that IDC had an 
additional HSR-type amplicon of ERBB2. These findings strongly indicate that IDC and 
ILC had a common precursor cell with CCND1 amplification. Review of the biopsy 
specimen with FISH showed IDC with gene amplifications of CCND1 and ERBB2 as a 
minor component, IDC without amplification of CCND1 or ERBB2 as a major 
component, and a minute portion of ILC with CCND1 amplification. We speculate that 
chemotherapy and trastuzumab caused a marked reduction in IDC; however, ILC with 
CCND1 amplification was resistant to chemotherapy and grew. 
 
 


















Invasive ductal and lobular breast carcinomas (IDC and ILC, respectively) are the 
most common histological types of invasive carcinoma of the breast. Molecular 
profiling studies, clinical and follow-up data, and common metastatic patterns suggest 
that these histological types of breast cancer have genetic and biologic differences.1, 2 
Tumors with mixed ductal and lobular morphology, referred to as mixed ductal and 
lobular carcinoma (MDLC), are relatively rare and account for 3%-8% of invasive 
breast cancers; the clinical and biological significance of MDLC is unknown, as few 
studies have focused on these tumors.3, 4  
ILC often have inactivating mutations or methylation silence of the E-cadherin 
gene (CDH1) mapping to chromosome 16q22.1 in combination with loss of the 
wild-type CDH1 allele.5 Thus, most ILC cases (85%) are completely 
E-cadherin-negative, while most IDC cases have no reduction or only a heterogeneous 
reduction in E-cadherin expression.2 Therefore, the negative immunostaining of 
E-cadherin is the critical diagnostic aid in the differential diagnosis of ILC.  
The CCND1 gene located on 11q13 is a cell-cycle regulatory gene that has been 
implicated in breast cancer progression.6 CCND1 amplification was associated with 
higher tumor grade, and patients with highly amplified CCND1 had a significantly 
worse prognostic score than the low amplification group.7 Although CCND1 is 
amplified in 5%-20% of primary breast cancers,8 the product of CCND1, cyclinD1, is 
overexpressed at the mRNA and protein level in over 50% of breast cancers without a 
straightforward association with the gene amplification.7  
Gene amplification of ERBB2 (also called HER2), which has been the target of 
molecular therapy, occurs in about 15% of breast cancers. In ILC, ERBB2 amplification 
is very rare as compared to in IDC,7 and the reported frequency of the CCND1 
amplification ranges greatly from 0% to 27% of cases.7, 9  
Multiplex ligation-dependent probe amplification (MLPA) is a new, high-resolution 
method for detecting numerous copy number variations in genomic sequences in a 
single reaction requiring only small amounts of DNA extracted from formalin-fixed 
paraffin-embedded (FFPE) tissues.10, 11 A detection kit for 21 genes frequently amplified 
and deleted in breast cancers, including ERBB2, CCND1 and CDH1, is commercially 
available. Here, we present a case of MDLC, in which the clonal profile could be well 
described by IHC, MLPA and fluorescence in situ hybridization (FISH). 
 
Clinical summary 
A 36-year-old woman presented with a palpable mass in her right breast in September 
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2007. Physical examinations revealed a tumor measuring approximately 7 cm in 
diameter in the upper medial quadrant of the right breast. A needle biopsy of the lesion 
revealed invasive ductal carcinoma. Immunohistochemically, estrogen receptor  
(ER ) and progesterone receptor (PgR) were positive in approximately 60% and 30% 
of the tumor nuclei, respectively. The HercepTestTM was also positive (score 3), as 
approximately 20% of the cancer cells showed unequivocal staining of the cytoplasmic 
membrane. Systemic examination revealed multiple metastases in the lymph nodes, 
liver, and bones. After six cycles of paclitaxel (80 mg/m2) and trastuzumab (4 mg/kg 
loading dose, followed by 2 mg/kg once per week) as a chemotherapy for the luminal 
B-like cancer, followed by four cycles of fluorouracil epirubicin (75 mg/m2) and 
cyclophosphamide (FEC)12 as systemic therapy, a right mastectomy and axillary lymph 
node dissection were performed for the purpose of disease control in spring 2008. The 
post-operative course was uneventful, but in October 2009 the patient died of brain 
metastasis. An autopsy was not performed. 
 
Surgical specimens 
An ill-defined tumor measuring approximately 8×7 cm was found. Histologically, the 
tumor consisted of cuboidal cells forming solid nests or tubules and smaller round cells 
growing discohesively (Fig. 1A). By immunohistochemistry (IHC), the former cells 
were E-cadherin positive and diagnosed as IDC, but the latter cells were negative for 
E-cadherin and considered to be ILC. Our diagnosis of the tumor was MDLC. (Fig. 1B)  
Metastatic cancer was found in 11 lymph nodes, and the histology was lobular 
carcinoma in seven nodes, ductal carcinoma in one node and MDLC in three nodes. 
The biopsy specimen was reviewed and reclassified as MDLC because a minute 
portion of ILC was found. Neither ductal carcinoma in situ nor lobular carcinoma in situ 
was found in the biopsy specimen or resected tumor. 
 
IHC  
Antibodies against ER (clone 6F11, Novocastra, Newcastle upon Tyne, UK; 
working dilution of 1:50), PgR (clone PgR636, DAKO A/S, Glostrup, Denmark, 
ready-to-use), the internal domain of human ERBB2 (polyclonal, Nichirei, Tokyo, 
Japan; working dilution of 1:100), E-cadherin (mouse monoclonal, NCH-38, DAKO; 
ready-to-use), human cyclin D1 (rabbit monoclonal, SP 4, Nichirei, ready-to-use) and  
Ki-67 antigen (mouse monoclonal, clone MIB-1, DAKO; working dilution of 1:100) 
were used. Antibodies were visualized by avidin-biotin binding to 
peroxidase-conjugated secondary antibodies (DAKO).  
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Cyclin D1 was positive in both IDC and ILC. ERBB2 was positive in IDC but negative 
in ILC (Fig. 1C). ER was positive in more than 80% of nuclei of ILC but negative in 
the nuclei of IDC. PgR was negative both in the ILC and IDC tumor nuclei. Ki 
67-positive nuclei were found in approximately 50% of IDC and ILC cells.  
 
MLPA 
Two representative tumor areas of IDC and ILC, approximately 0.5 cm2 and 1.0 cm2 
respectively, were identified on consecutive 6-m-thick sections by using adjacent 
HE-stained sections. DNA was extracted separately and manually according to the 
manufacturer’s protocol. MLPA analysis was performed by using a kit (SALSA MLPA 
KIT P078-B1 Breast Tumour) from MRC-Holland (Amsterdam, The Netherlands). This 
kit contains 39 probes for 21 different genes (ESR1, EGFR, FGFR1, ADAM9, IKBKB, 
PRDM14, MTDH, MYC, CCND1 C11orf30, CDH1, TRAF4, CPD, MED1, ERBB2, 
CDC6, TOP2A, MAPT, BIEC5, CCNE1, and AURKA), including four probes for ERBB2, 
two probes for CCND1, two probes for CDH1 and one probe for MED1. Data analysis 
was performed with Coffalyser MLPA-DAT software (version 9.4, MRC-Holland) to 
generate normalized peak values. Peak values below 0.7 were defined as lost, between 
0.7 and 1.3 as normal, between 1.3 and 2.0 as gain, and values >2.0 as amplified, as 
previously established.11 
The results showed that CCND1 was amplified both in IDC and ILC, however 
ERBB2 and MED1 were amplified only in IDC, and CDH1 was within the normal range 




FISH probes for ERBB2 (RP11-62N23), CCND1 (RP11-775J10) and 
CDH1(RP11-354M1) were acquired from BACPAC Resources (Oakland, CA, USA) 
and labeled with SpectrumOrangeTM or SpectrumGeenTM with a nick translation kit 
(Abbott Laboratories, Abbott Park, IL, USA). For the detection of gene amplification, 
SpectrumGreenTM-labeled pericentromeric probes (Abbott) specific to chromosomes 11, 
16 and 17 on which the particular gene was located were co-hybridized to standardize 
the chromosome number. 
 By FISH on paraffin-embedded surgical specimens, clustered signals of CCND1 
corresponding to gene amplification on a homogeneously staining region (HSR) 13 were 
found in both IDC and ILC; however, similar clustered signals of ERBB2 were only 
found in IDC. (Figs. 2A and B.). The copy numbers of ERBB2 and CEP17 were 
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18.0±4.5 (mean±SD) and 3.0±2.7, respectively, and their ratio was 8.3±4.7. The copy 
numbers of CCND1 and CEP11 were 9.1±2.6 and 1.4±0.6, respectively, and their ratio 
was 7.1±2.9. Dual-color FISH on a biopsy specimen showed that approximately a 
quarter of IDC cells had HSR signals of both ERBB2 and CCND1; however 70% were 
negative for ERBB2 and CCNDI. (Figs. 2C and D) 
Touch smears of fresh tumor prepared immediately after surgery were also used for 
the FISH analysis. Dual-color FISH for CCND1 and ERBB2 revealed two types of 
unequivocal tumor nuclei: nuclei with clustered signals of CCND1 and ERBB2, and 
smaller nuclei with clustered signals of only CCND1. (Fig. 3A) Each signal corresponds 
to the nucleus of IDC and that of ILC in paraffin-embedded surgical specimens, 
respectively. Interestingly, the FISH images of amplified CCND1 in IDC and ILC 
appeared similar in size and shape. (Fig. 3A) Dual-color FISH of CDH1 and centromere 
11 showed two predominant patterns for the number of CDH1 signals/number of 
centromere 11 signals; 2/2 and 1/1, as shown in Figures 3B and C.  
This study was approved by the Institutional Review Board at Kanazawa University 




The present case was a morphologically and immunohistologically typical MDLC. 
The MLPA analysis of the IDC revealed clear gene amplification of ERBB2 and 
CCND1; furthermore, the FISH analysis showed that the IDC contained amplified 
CCND1 and ERBB2 in HSRs although the ILC contained amplified CCND1 alone. In 
addition, the FISH analysis on touch smears showed that the IDC and ILC appeared to 
share similar HSR-type gene amplification of CCND1. High-level gene amplification 
associated with such well recognized abnormal chromosomal structure as HSR is 
mechanistically distinct from other forms of DNA copy number change and an 
important cytogenetic marker of cancer clones.13 Thus, in terms of tumorigenesis, it is 
most likely that the two cancer subclones found in the present tumor share a common 
precursor cell as drawn in Figure 4. 
 
The co-existence of two HSRs of CCND1 and ERBB2 in single nuclei of the IDC 
indicates the present tumor has a chromosomal instability phenotype; however, the 
cytogenetic mechanisms of co-amplification of ERBB2 and CCND1, which are located 
on different chromosomes, are enigmatic. At the present time, the selective merit, if any, 
of co-amplification of ERBB2 and CCND1 is unknown. A FISH study examining 93 
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cases of IDC reported high-level amplification of CCND1 and ERBB2 in 15% and 17%, 
respectively; however, there was no statistical significance for the frequent 
coamplification.9 A recent MLPA study identified ERBB2 and CCND1 coamplification 
in 9% of the examined invasive breast cancers,10 but it was not determined if the 
coamplifications occurred in a single nuclei or on the same amplicon. Different from 
CCND1 and ERBB2, genes such as MED1 located very closely to ERBB2 are 
occasionally co-amplified with ERBB2, as found in the present case as a molecular 
variant of ERBB2 amplicons.14 Whether it simply represents co-amplification of a 
‘passenger gene’ or it implicates reduced sensitivity to hormone therapy of 
ERBB2-amplified tumors remains to be clarified.14 
 
Negative expression of E-cadherin in ILC is considered to be caused by missense 
mutation or methylation silence of E-cadherin of an allele of CDH1 in combination with 
loss of the other normal allele by physical deletion of the chromosomal foci of 16p22.5 
The cancer cells with a single copy of CDH1 found by FISH on touch smear in the 
present study most probably correspond to the ILC. Deletion of one copy of the gene, 
which occurred in a subset of tumor cells, could not be detected by MLPA, which 
examines the net numerical changes.  
 
In the present study, three different cancer clones with different genetic profiles were 
found in specimens obtained pre- and post-systemic therapy: IDC with amplification of 
both CCND1 and ERBB2, IDC without the gene amplifications, and ILC with CCND1 
amplification. We speculate that systemic therapy caused clonal selection in the tumor, 
as depicted in Figure 4. The IDC cells without amplification of ERBB2 and CCND1 
found predominantly in the biopsy specimen may have been killed in response to the 
chemotherapy. However, the CCND1-positive cells were more resistant to the 
chemotherapy and survived. In fact, CCND1-amplified tumors are associated with 
treatment resistance and reduced survival times as compared to CCND1-positive [Is this 
correct?] cells.8 ILCs are generally less responsive to chemotherapy in relation to their 
biological characteristics.1, 15 As a result, the CCND1-amplified and 
ERBB2-non-amplified ILC, which is chemotherapy-resistant and 
trastuzumab-insensitive, became predominant as shown in Table 1. Interestingly, a 
recent study has reported that it was not infrequent that IDC carcinomas diagnosed on 
the core biopsy turned out to only have either lobular or another type of tumor in the 




The present case showed that the semi-comprehensive analysis of amplification status 
by MLPA could be useful to plan individualized molecularly targeted therapy against 
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Representative histology of the MDLC (A). E-cadherin (B) and ERBB2 (C) were 
positive in IDC, but negative in ILC.   
 
Figure 2.  
FISH on FFPET. In the resect tumor, IDC and IDC had gene amplification of CCND1 
(A: CCND1, orange fluorescence; centromere 11, green fluorescence); however, 
amplification of ERBB2 was confined to IDC (B: ERBB2, orange fluorescence; 
centromere 17, green fluorescence). The biopsy showed IDC with both CCND1- and 
ERBB2-amplification (C) and those without amplification (D) (CCND1, orange 
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fluorescence; ERBB2, green fluorescence). 
 
Figure 3. 
FISH on touch smears. Cancer nuclei with a cluster of amplified CCND1 (orange 
signals) and a cluster of amplified ERBB2 (green signals) and cancer nuclei with a 
clustered signal of CCND1 were found (A). In panels B and C, cancer cells with two 
copies and one copy of CDH1 were found, respectively. (Orange signal, CDH1; green 
signal, centromere 11.) 
 
Figure 4. 




Result of the MLPA analysis. Bold font indicates 'amplification' by MLPA; Italic font 
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IDC 0.97 0.94 1.15 0.93 1.21 1.13 0.88 0.96 1.01 1.2 0.98 1.02 0.75 1.06 1.03 3.11 3.28 1.17 1.05
ILC 0.85 0.95 1.04 0.91 1.11 1.05 0.85 0.87 1.01 1.05 1.01 0.97 0.99 1.13 0.95 2.86 2.97 1.11 1.04
TRAF4 CPD MED1 CDC6 MAPT AURKA
17q11 17q11 17q12 17q21 17q21 20q13
1 0.95 1.26 1.1 2.19 2.24 1.64 2.2 1.92 0.85 1.04 1.03 0.92 0.81 0.84 1.12 0.98 0.92 0.93 0.85
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